Looking To Learn From Past Failures, Galapagos Pivots To Immunology And CAR-T

200 Jobs Shed And Pipeline Cut Back

 
• By Andrew McConaghie

The company has admitted making mistakes in its R&D, but must now convince investors that its new multi-modality approach will pay off.

Cocoon
Galapagos has acquired Cellpoint and its point-of-care manufactured CAR-T technology called 'Cocoon'. • Source: Galpagos

More from Business

More from Scrip